Peripheral blood hematopoietic stem cells will not be taken for the production of cultured RBC unless the graft destined for the patient contains > 7x106 CD34+ cells/kg body weight of the patient receiver, the cell dose established in the literature as being sufficient to reconstitute the hematopoiesis of a patient receiving an allogenic graft. Thus the research protocol will incur no loss of chance for the patient.